- IBUFENAC
-
- $15.00 / 1KG
-
2021-07-13
- CAS:1553-60-2
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
- IBUFENAC
-
- $15.00 / 1KG
-
2021-07-10
- CAS:1553-60-2
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
|
| IBUFENAC Basic information |
| IBUFENAC Chemical Properties |
Melting point | 85-87°C | Boiling point | 288.25°C (rough estimate) | density | 1.0240 (rough estimate) | refractive index | 1.5100 (estimate) | storage temp. | Sealed in dry,Store in freezer, under -20°C | solubility | Chloroform (Slightly), Methanol (Slightly) | form | Solid | pka | 4.36±0.10(Predicted) | color | White to Off-White |
HS Code | 2916399090 | Toxicity | LD50 orally in mice: 1.8 g/kg (Adams) |
| IBUFENAC Usage And Synthesis |
Chemical Properties | Crystalline Solid | Uses | Used as an analgesic, anti-inflammatory. | Definition | ChEBI: A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a 4-isobutylphenyl group. Although it was shown to be effective in treatment of rheumatoid arthritis, the clinical use of ibufenac was discontinued due to hepatot
xic side-effects. | Biological Activity | ibufenac is a dual cox-1 and -2 inhibitor.cyclooxygenase (cox), also known as prostaglandin-endoperoxide synthase (ptgs), is an enzyme that is responsible for formation of prostanoids, such as thromboxane and prostaglandins. | in vitro | ibufenac was identified as an analog of the nsaid ibuprofen that could inhibit cox-1 and -2 activity with ic50 values of 17.4 and 13.1 μm, respectively [1]. | in vivo | in a previous animal study, two new structural analogs, r3 and r4, along with their parent compounds, ibufenac and ibuprofen, were evaluated for their biopharmaceutical properties. aanti-inflammatory activity was evaluated by topically administering drugs to inhibit inflammation induced by using either clove oil or arachidonic acid. results showed that the rank order of activity was ibufenac approximately equal to ibuprofen > r3 approximately equal to r4 [2]. | IC 50 | 17.4 and 13.1 μm for cox-1 and -2, respectively. | references | [1] gülcan, h. o.,nlü, s.,dimoglo, a., et al. marginally designed new profen analogues have the potential to inhibit cyclooxygenase enzymes. arch.pharm.chem.life sci. 348, 55-61 (2015). [2] rao cs, schoenwald rd, barfknecht cf, laban sl. biopharmaceutical evaluation of ibufenac, ibuprofen, and their hydroxyethoxy analogs in the rabbit eye. j pharmacokinet biopharm. 1992 aug;20(4):357-88. [3] t. m. chalmers. |
| IBUFENAC Preparation Products And Raw materials |
|